The high positive prediction rates for MAN2A1-FER (88.2%), SLC45A2-AMACR (75%) and Pten-NOLC1 (90.9%) between blood samples and the primary prostate cancer samples suggests that the source of the fusion transcripts in the blood samples is likely prostate cancer. Here, PTEN is linked to prostate cancer.